Healthcare Technology Featured Article

February 26, 2013

Use of Tissue Sealants and Topical Haemostats on the Rise



Frost and Sullivan’s analysis report on the Tissue Sealants and Topical Haemostats Market (Western European) found a higher use of these products due to the increase in surgical volume. Driving factors for the increases in tissue sealants and hemostats were the need for quality care of a rapidly aging population and technical advancements of products that enhance patient safely and surgical efficiency, .i.e. sealants with drug-delivery applications, ease-of-use applicator systems for surgeons and development of recombinant and plant-based and combinatory products. 

In addition, the analysis concluded that the market earned $438.1 million in 2011 and estimates this to reach $685.5 million in 2016. The research covers tissue sealants (fibrin and synthetic) and topical haemostats (gelatine-based, collagen-based, thrombin-based, oxidized-regenerated cellulose-based and combination).

"The demand for tissue sealants and topical haemostats products is directly proportional to the total number of surgical procedures performed," notes Frost & Sullivan Research Analyst Brahadeesh Chandrasekaran. “As Europe's population ages, the volume and range of surgical procedures conducted is set to increase. This will promote demand for tissue sealants and topical haemostats, because both peri-operative and post-operative bleeding requires immediate attention during complex surgeries."

Presently, sealants and haemostats use have high benefits with no complications, however, there have been concerns related to infection-associated risks and biocompatibility due to products containing animal-derived components and the risk of transmission of viral diseases inherent in plasma-derived products.

“This has triggered significant growth in plant-based and combinatory products, because they have proven to be safe for patients," remarks Chandrasekaran. “Manufacturers that already have green or plant-based products have an edge, provided their products are backed by strong clinical evidence."




Edited by Brooke Neuman




comments powered by Disqus


FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]

From White Paper Library